IND clearance for OXU-001
We are thrilled to announce the IND clearance for suprachoroidal OXU-001, supporting it’s advancement into
We are thrilled to announce the IND clearance for suprachoroidal OXU-001, supporting it’s advancement into
Oxular’s CMO, Friedrich Asmus, MD, spoke at the Dry AMD Therapeutic Development conference in Boston, presenting
OXFORD, UK – November 7, 2022 – Oxular Limited, a clinical-stage retinal therapeutics company developing
Oxular is thrilled to sponsor ISU 2022 in Utrecht, The Netherlands, and introduce the Oxulumis®
An excellent summary about the potential of our lead program, OXU-001, from Drug Discovery World.
Oxular’s Senior Medical Advisor, Prof. Marc de Smet, presented on “Managing CME via the Suprachoroidal
Oxular’s Chief Scientific Officer, Ron Yamamoto, shared an overview of Oxular’s drug delivery formulations at
Our CEO, Tom Cavanagh, presented an overview of Oxular’s retinal therapeutics platform at Eyecelerator, during
Oxular was mentioned in this great article by Dr. Sivaprasad in Retina Today, on the
Our Site
General Contact
+44 (0)1865 636200
Magdalen Centre
1 Robert Robinson Avenue
Oxford, OX4 4GA, UK
Media Contact
Ben Atwell / Alex Davis
FTI Consulting
London
Limited company registered in England and Wales (Registration No. 09331313)
VAT No. GB 244 5883 81
Copyright Oxular Limited
Website designed by Emerald Grove Studio
Website built by THRH Consulting
Follow us on
Limited company registered in England and Wales (Registration No. 09331313) VAT No. GB 244 5883 81
Copyright Oxular Limited
Website designed by Emerald Grove Studio
Website built by THRH Consulting